Previous 10 | Next 10 |
Genprex ([[GNPX]] +0.4%) has passed the final release tests of scaled-up clinical grade production to supply REQORSA immunogene therapy for upcoming Acclaim-1 and Acclaim-2 trials in non-small cell lung cancer.The company recently announced the completion of the techn...
Company passes final release tests of scaled-up clinical grade production to supply drug product for upcoming Acclaim-1 and Acclaim-2 clinical trials in lung cancer Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-sta...
Proceeds will add resources for the Company’s Acclaim-1 and Acclaim-2 clinical trials in lung cancer, as well as its pre-clinical programs in cancer and diabetes Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage ge...
Gainers: Air T (AIRT) +156%.FAT Brands (FAT) +85%.Addex Therapeutics (ADXN) +72%.Senseonics Holdings (SENS) +57%.SIFCO Industries (SIF) +45%.Gevo (GEVO) +44%.Neoleukin Therapeutics (NLTX) +42%.Avinger (AVGR) +41%.IZEA Worldwide (IZEA) +23%.Harvest Capital Credit (HCAP) +20%.Losers: Jagua...
Lizhi (LIZI) +29%.Ekso Bionics Holdings (EKSO) +25%.AgEagle Aerial Systems (UAVS) +22%.ENGlobal Corporation (ENG) +23%.Supernus Pharmaceuticals (SUPN) +23%.Scopus BioPharma (SCPS) +21%.Mogo (MOGO) +18%.Magnite (MGNI) +18%.Kopin Corporation (KOPN) +18%.Magna International (MGA) +18%.InMed Phar...
Genprex ([[GNPX]] +11.1%) inks agreement with a single healthcare-dedicated institutional investor for the purchase and sale of ~3.12M shares at a purchase price of $3.85/share in a registered direct offering priced at-the-market.No warrants will be issued in connection with the tra...
The clinical-stage micro-cap, Genprex (GNPX), is up +13.6% after the company announced the completion of manufacturing scale-up for its lead product candidate, REQORSA™ immunogene therapy targeting non-small cell lung cancer.Subject to passing final testing currently und...
Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into a securities purchase agreement with a si...
Gainers: Ocugen (OCGN) +90%, NantHealth (NH) +35%, Organovo (ONVO) +25%, Genprex (GNPX) +23%, Spero Therapeutics (SPRO) +14%.Losers: Soligenix (SNGX) -54%, SOS (SOS) -39%, Venus Concept (VERO) -23%, BioCryst Pharmaceuticals...
Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, expected to grow to $26.3 Billion by 2023 Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale Genprex, Inc. ...
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...